Novartis (NVS) Misses Q3 EPS by 4c

Novartis (NYSE: NVS) reported Q3 EPS of $1.27, $0.04 worse than the analyst estimate of $1.31. Revenue for the quarter came in at $12.3 billion versus the consensus estimate of $12.66 billion.

Commenting on the results, Joseph Jimenez, CEO of Novartis, said:

"Novartis continued to make strong progress on innovation and key launches in the third quarter. The Pharmaceuticals and Sandoz Divisions continue to perform exceptionally well, offsetting softness in the Alcon Division. Entresto was approved and launched in the US, and Tafinlar + Mekinist was approved in the EU for BRAF-mutant melanoma. We confirm our full-year guidance."

For earnings history and earnings-related data on Novartis (NVS) click here.

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Regions Financial (RF) Misses Q1 EPS by 8c
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance